SWOG clinical trial number

CTSU/EA1181

(CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response. Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)

Open

Phase

Abbreviated Title

CompassHER2-pCR

Activated

02/11/2020

Participants

ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Breast Cancer

Treatment

Paclitaxel Docetaxel Trastuzumab Nab-Paclitaxel Pertuzumab

Eligibility Criteria Expand/Collapse

Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org).

Other Clinical Trials

SWOG Clinical Trial Number

S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer

Research Committee(s)

Breast Cancer

Symptom Control and Quality of Life

Activated

10/30/2023

Accrual

3%

Open

Phase

SWOG Clinical Trial Number

S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)

Research Committee(s)

Breast Cancer

Activated

07/21/2023

Accrual

8%

Open

Phase

SWOG Clinical Trial Number

CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer

Research Committee(s)

Breast Cancer

Activated

06/07/2021

Open

Phase